Dr. Petra Brückner

i2i Lead Germany bei UCB Pharma GmbH

Hilden, North Rhine-Westphalia, Germany

About

Experience

  • UCB Deutschland (20 yrs 10 mos)
    • i2i Lead Germany
      Dec 2023 - Present · 2 yrs 7 mos

      As part of UCB’s sustained and strategic commitment to patients, UCB will continue to focus on fact-based decision making. To enable this, regional Insights-to-Impact (i2i) functions have been established within the corporate development & finance function, which are acting as independent sparring partner to the go-to-market Patient Value units providing Insights for performance understanding & management and resource allocation recommendations, while performing business planning.

    • Franchise Head Epilepsie und seltene Epilepsiesyndrome
      Apr 2022 - Nov 2023 · 1 yr 8 mos

      Leitung des Commercial und Medical Innen- und Außendienstteams mit der Zielgruppe Neurologen/Epileptologen mit dem Schwerpunkt Epilepsie und seltene Epilepsiesyndrome

    • Ecosystem Head Neurology Central Europe
      Jan 2020 - Mar 2022 · 2 yrs 3 mos

      Maximize the G2M in Epilepsy, integrate Zogenix with Fintepla and prepare the RARE EPI skills and execute the strategy

  • Regional Field Manager Commercial at Eisai GmbH
    Oct 2001 - Aug 2005 · 3 yrs 11 mos

    Specialists in the Therapeutic Area of CNS and Gastrointestinal Diseases at Eisai GmbH, Coaching of 3 Colleagues and responsible for regional skill training

  • Scientific Hospital Field Service Partner at Wyeth-Pharma GmbH
    Mar 2000 - Sep 2001 · 1 yr 7 mos

    Medical fieldforce focused on Infectiology/ Oncology